同步脂质体紫杉醇和顺铂化疗改善了接受调强放疗的局部晚期食管鳞状细胞癌的治疗效果。
Concurrent liposomal paclitaxel and cisplatin chemotherapy improved outcomes for locally advanced esophageal squamous cell carcinoma treated with intensity-modulated radiotherapy.
作者信息
Liu Shu, Ren Sheng-Nan, Ding Wen-Xiu, Ge Xiao-Lin, Cao Yuan-Dong, Zhang Sheng, Zhen Fu-Xi, Sun Xin-Chen
机构信息
Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Department of Oncology, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211100, China.
出版信息
Ann Transl Med. 2019 Jul;7(14):331. doi: 10.21037/atm.2019.06.45.
BACKGROUND
To ascertain whether concurrent chemotherapy using liposomal paclitaxel and cisplatin could improve the outcomes of patients with locally advanced esophageal squamous cell carcinoma receiving intensity-modulated radiotherapy (IMRT).
METHODS
A total of 72 patients with locally advanced esophageal squamous cell carcinoma, which were admitted to our hospital from October 2011 to December 2013, were retrospectively analyzed in this study.
RESULTS
Thirty-six patients (50%) were treated with IMRT alone, while the other 36 patients (50%) were treated by IMRT combined with chemotherapy containing liposomal paclitaxel and cisplatin. Patients treated with chemoradiotherapy showed significantly superior overall survival (OS) and progression-free survival (PFS) compared to patients treated with IMRT alone (median OS: respectively, 29.7 12.9 months, P=0.0287; median PFS: respectively, 14.0 6.5 months, P=0.0186). Multivariate Cox analysis confirmed the inclusion of chemotherapy as an independent predictor of favorable OS and PFS. Both chemoradiotherapy and IMRT were well-tolerated in our cohort.
CONCLUSIONS
Chemotherapy improved the prognosis of locally advanced esophageal squamous cell carcinoma treated with IMRT. Large prospective studies are needed to confirm the therapeutic value of IMRT combined with chemotherapy in locally advanced esophageal squamous cell carcinoma.
背景
为确定使用脂质体紫杉醇和顺铂的同步化疗能否改善接受调强放疗（IMRT）的局部晚期食管鳞状细胞癌患者的预后。
方法
本研究回顾性分析了2011年10月至2013年12月期间我院收治的72例局部晚期食管鳞状细胞癌患者。
结果
36例患者（50%）仅接受IMRT治疗，另外36例患者（50%）接受IMRT联合含脂质体紫杉醇和顺铂的化疗。与仅接受IMRT治疗的患者相比，接受放化疗的患者的总生存期（OS）和无进展生存期（PFS）显著更长（中位OS：分别为29.7个月对12.9个月，P = 0.0287；中位PFS：分别为14.0个月对6.5个月，P = 0.0186）。多因素Cox分析证实化疗是OS和PFS良好的独立预测因素。在我们的队列中，放化疗和IMRT的耐受性均良好。
结论
化疗改善了接受IMRT治疗的局部晚期食管鳞状细胞癌患者的预后。需要开展大型前瞻性研究以证实IMRT联合化疗在局部晚期食管鳞状细胞癌中的治疗价值。
Zotero 插件